Cancer patients get lifeline: continued access to promising drugs
NCT ID NCT06174987
Summary
This study allows patients with advanced or metastatic cancer who are benefiting from certain experimental drugs to continue receiving them after their original trial ends. It aims to provide continued treatment access while closely monitoring for any long-term side effects. The study is open to about 50 participants who are not showing disease progression and are already enrolled in related Daiichi Sankyo or AstraZeneca trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
A.C. Camargo Cancer Center
NOT_YET_RECRUITINGSão Paulo, Brazil
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Complejo Hospitalario Universitario A Coruña
RECRUITINGA Coruña, 15006, Spain
-
Duke University - Trent Center
RECRUITINGDurham, North Carolina, 27710, United States
-
Flinders Medical Center
ACTIVE_NOT_RECRUITINGBedford Park, 5042, Australia
-
Grand Hôpital de Charleroi
RECRUITINGCharleroi, 6000, Belgium
-
Hospital Ruber Internacional
WITHDRAWNMadrid, 28034, Spain
-
Hospital Universitari Dexeus
NOT_YET_RECRUITINGDistrito de Les Corts, 08028, Spain
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
IBCC Nucleo de Pequisa e Ensino
NOT_YET_RECRUITINGSão Paulo, Brazil
-
ICO l'Hospitalet - Hospital Duran i Reynals
RECRUITINGL'Hospitalet de Llobregat, 08908, Spain
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
Instituto Aericas
NOT_YET_RECRUITINGRio de Janeiro, Brazil
-
Istituto Nazionale Tumori Fondazione G. Pascale
WITHDRAWNNaples, 80131, Italy
-
Kyungpook National University Chilgok Hospital
RECRUITINGDaegu, 41404, South Korea
-
Miami Cancer Institute
RECRUITINGMiami, Florida, 33176, United States
-
Monash Medical Center
WITHDRAWNMelbourne, 3168, Australia
-
National Cancer Center
RECRUITINGGyeonggi-do, 10408, South Korea
-
National Cancer Center Hospital
RECRUITINGChūō, 104-0045, Japan
-
National Cheng Kung University Hospital
WITHDRAWNTainan, 704, Taiwan
-
National Taiwan University Hospital
WITHDRAWNTaipei, 10002, Taiwan
-
Ospedale San Raffaele
RECRUITINGMilan, 20132, Italy
-
Rabin Medical Center
ACTIVE_NOT_RECRUITINGPetah Tikva, Israel
-
Royal Surrey County Hospital
WITHDRAWNGuildford, GU2 7XX, United Kingdom
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Seoul National University Bundang Hospital
WITHDRAWNGyeonggi-do, 13620, South Korea
-
Seoul National University Hospital
RECRUITINGJongno-gu, 03080, South Korea
-
Severance Hospital, Yonsei University
RECRUITINGSeoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.